**PGN-OB2** is a GLP-1 agonist and [[OBDS|OBDS]] [[Combination Products|drug device combination]]. The specific GLP-1 agonist is not disclosed at this time. Expected to treat diabetes as part of the [[Systemic Therapeutics Pipeline|Systemic Therapeutics Pipeline]]. > [!quote] PGN-OB2: liquid formulation of a GLP-1 receptor agonist delivered with the OBDS for the treatment of Type 2 diabetes > We are developing PGN-OB2 as a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. GLP-1RAs are a leading class of therapeutics for type 2 diabetes. We believe oral GLP-1RAs will be preferred by patients to injectables, resulting in a significant market opportunity. > > We are currently advancing development of PGN-OB2 with key preclinical studies. As a result of our use of known molecules, we believe that rapid proof of concept with preclinical and phase 1 pharmacokinetic results is possible. > > Source: <https://www.bioratherapeutics.com/pipeline/systemic-therapeutics>